What You’ll Do

You will report to the Senior Director, Market Access, EU Center and work closely with Medical Affairs, HEOR, Regulatory, Commercial and our global Market Access team to secure and sustain patient access to BridgeBio’s medicines across the DACH region. Your remit is to own the German AMNOG process end to end – from the value dossier under § 35a SGB V through the reimbursement price negotiation with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) under § 130b SGB V – and regional market access, which turns that outcome into real-world access through direct engagement with sickness funds, the Medical Service, regional physicians’ associations, hospitals and treating centres. You will also lead reimbursement submissions in Austria and Switzerland. This role requires effective collaboration with cross-functional colleagues and external stakeholders to ensure high-quality execution and impact. The ideal candidate combines deep AMNOG and HTA expertise with strong communication skills, adaptability, and the ability to thrive in a fast-paced, hands-on environment.

Responsibilities

• Lead AMNOG value dossiers end to end: plan, resource, quality-assure and submit complete dossiers under § 35a SGB V to the Federal Joint Committee (G-BA), including derivation of the appropriate comparator therapy (zVT), early identification of evidence gaps and defensible argumentation on indirect comparisons, surrogate and subgroup analyses
• Own G-BA and IQWiG interactions: prepare scientific advice requests under § 8 AM-NutzenV, run written commenting procedures and oral hearings, and manage all procedural communication and timelines
• Prepare and support price negotiations: develop pricing strategy, negotiation mandate, scenarios and European reference price analyses for the negotiation with the GKV-Spitzenverband under § 130b SGB V, and plan realistically for arbitration board risk
• Drive regional payer engagement: engage sickness funds at federal and regional level, the Medical Service (MD) and regional physicians’ associations (KVen) on reimbursement, cost-efficiency reviews and prior-authorisation practice, and translate those insights into regional access concepts
• Secure hospital and clinic reimbursement: advise treating centres on NUB applications, DRG and additional-payment (ZE) mapping, budget and price negotiations, drug committees and formulary listing, including outpatient care via ASV under § 116b SGB V
• Resolve access barriers in the field: handle individual reimbursement requests, denials and claw-backs together with Medical Affairs and the field teams, and turn recurring issues into argumentation aids and training material
• Extend access beyond Germany: lead reimbursement submissions in Austria (EKO) and Switzerland (FOPH Specialities List), and bring market access requirements into study design, evidence planning and launch planning across the cross-functional team

Where You’ll Work 

• This is a Germany-based remote role
• Approximately 20% travel is anticipated – for G-BA and GKV-Spitzenverband meetings in Berlin, regional payer and hospital meetings across Germany, selected meetings in Austria and Switzerland, and as-needed visits to our International HQ in Zug

Who You Are

• Degree in health economics, pharmacy, medicine, life sciences or a comparable field
• 5–8 years of experience in market access or HTA – in the pharmaceutical industry, a consultancy or a specialised HTA service provider
• Demonstrated experience preparing AMNOG value dossiers under § 35a SGB V, ideally as project lead on at least one complete procedure, plus hands-on involvement in a reimbursement price negotiation under § 130b SGB V
• Solid command of G-BA and IQWiG methodology, procedural rules and statutory timelines, with the ability to appraise clinical evidence critically and translate it into payer-ready argumentation
• Experience engaging payers and/or hospitals directly on reimbursement matters, and the confidence to lead those conversations yourself; knowledge of German hospital financing (NUB, DRG, additional payments) and of reimbursement in Austria and Switzerland is a strong plus
• Strong written argumentation and the ability to work autonomously in an environment where some processes are still being built; experience with orphan drugs or a limited evidence base is an advantage
• Business-fluent German and English
• Willingness to travel approximately 20% of working time

Rewarding Those Who Make the Mission Possible

We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return.

• Market-leading compensation
• Hybrid work model – we value your flexibility in how you work, but encourage time in the office to strengthen our culture, collaboration, and sense of community
• We provide career development through regular feedback, continuous education and professional development programs
• We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities.